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The rat prostate, a classical androgen-target tissue, contains both known isozymes of steroid 5q~ 
reductase, i.e. type I and type II. So far, the role of the type I isozyme has been proposed as 
catabolic. The abundant expression of type I 5a-reductase in an androgen-target tissue is 
therefore puzzling. Assessment of the subcellular localization of 5a-reductase isozymes in rat prostate 
might contribute in elucidating their possibly distinct roles. After obtaining crude subcellular fractions 
by differential centrifugation, both isozyme activities were measured at neutral pH by plotting 
according to Eadie-Scatchard. The observations were extended by assessment of pH-dependent 
velocity ratios and type II 5a-reductase inhibitor sensitivities in these subcellular fractions. The 
results indicated a preferentially—although not exclusively—nuclear localization for the type I and a 
predominantly microsomal localization for the type II isozyme activity in the rat prostate. In 
conclusion, the nuclear localization of the type I isozyme seems not to concur with its proposed 
catabolic role.
AGH Smals, Department of Medicine, Division of Endocrinology, University Hospital Nijmegen, Geert 
Grooteplein Zuid S, 6 5 2 5  GA Nijmegen, The Netherlands
Steroid 5a-reductase (3-oxo-5a-steroid A 4-reductase, 
E.C. 1.3.1.22) is a membrane-bound, NADPH-depen- 
dent enzyme capable of 5a-reducing a number of 
steroids with a 4,5-double bond and a 3-oxo group, 
including androgens (1).
The enzyme 5a-reductase was first described in rat 
liver (2, 3), where it was considered to function as a 
catabolic enzyme. After 5a-reduction, steroids are 
susceptible to 3 a- and 3/3-hydroxysteroid dehydrogena­
tion, sulphation and glucuronylation, facilitating their 
excretion (1). Later, 5a-reductase activity was also 
found in rat prostate (4-7), a classical androgen-target 
tissue. As dihydro testosterone (DHT) accumulated in 
the nuclei of prostatic cells after administration of 
radiolabelled testosterone to rats (4, 8), and as DHT 
appeared to be a more potent androgen than testoster­
one in binding to the androgen receptor (9, 10), an 
anabolic role for the prostatic 5a-reductase has been 
suggested. To date, two subtypes of steroid 5a-reductase 
with specific pH optima and inhibitor sensitivities, 
designated type I and type II, have been described in 
both hum an and rat (11-16). Both the catabolic and 
anabolic roles proposed for 5a~reductase could be 
attributed to the respected isozymes, based on their 
tissue-specific localization— type I being found in the 
liver, type II being the predominant isozyme in the 
prostate— and based on their respective affinity con­
stants (16).
Studies on the subcellular distribution of 5 a- 
reductase activity in the rat prostate show a wide 
variety of results. Investigators found nuclear-bound rat 
prostatic 5a-reductase, yet with a considerable am ount 
of enzyme activity in mitochondrial and microsomal 
fractions, ranging from 24% to as high as 74% of total 
activity (6, 1 7 -2 0 ). These latter activities, however, 
might have arisen from nuclear contam ination, as has 
been described for the hum an  prostate (21). Subsequent 
research focused on the characterization, purification 
and solubilization of the nuclear-bound prostatic 5a- 
reductase activity (6, 7, 17, 20, 22). It is now 
recognized tha t the rat prostate expresses both 
isozymes of Sa-reductase (16). Immunocytochemical 
studies established a nuclear localization of 5a- 
reductase immunoreactivity— probably attributable 
to the type I isozyme— in rat prostate epithelium (23). 
To the best of our knowledge, the subcellular localiza­
tion of 5a-reductase isozyme activities in ra t prostate 
has not yet been elucidated.
In the present study, the subcellular distribution of 
5a-reductase isozyme activities in .the ra t prostate was 
investigated to gain better insight into the functional 
roles of both isozymes. The results suggest a differential 
subcellular distribution of the two subtypes in this 
tissue, based on activity measurements, isozyme-specific 
pH-dependent velocity ratios and inhibitor sensitivities 
of 5a-reductase activity in crude subcellular fractions.
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Materials and methods
Materials
[ 1,2,6,7-3H]Testosterone (3.74TBq/mmol) and [ la .2 a  
(n)~3H]17/3-hydroxy-5a-androstan-3-one (2.00 TBq/ 
mmol) were purchased from Amersham (Amersham, 
UK). [ 9 , l l - 3H]5a~Androstane-3a,17/?-diol (1 .4 8 TBq/ 
mmol) was obtained from Du Pont-New England 
Nuclear (Boston, MA). All radiolabelled steroids were 
purified by high-performance liquid chromatography 
(HPLC, see below) before use. Testosterone was 
purchased from Steraloids (Wilton, NH). Diethylether 
(p.a.), n-hexane (LiChrosolv) and 2-propanol (LiChro- 
solv) were purchased from Merck (Darmstadt, 
Germany). All other chemicals used were of analytical 
grade. The specific ra t 5a-reductase type II inhibitor L- 
685,273 (21,21 -pen tame thy lene-4~ aza- 5 a-pregn-1 - 
ene-3,20-dione) was a kind gift from Merck, Sharp 
and Dohme Corp. (Rahway, NJ).
Buffers
The homogenization buffer consisted of 20 mmol/1 
phosphate (Merck), 1 mmol/1 monothioglycerol, 
50 ¿¿mol/1 NADPH tetrasodium salt (Merck) and
0.25 mol/1 sucrose (Merck) (pH 7.0). The incubation 
buffer consisted of 200 mmol/1 TRIS (2-amino-2- 
hydroxymethylpropane-l,3-diol, Merck)/citric acid mono­
hydrate (Merck) and 2 mmol/1 NADPH (pH 5.0 or 7.0).
Animals and tissue preparation
Ten Wistar rats from the local breeding facility of 7 -1 3  
weeks old ( 1 5 0 - 2 5 0 g) were killed by decapitation 
and whole prostates were removed, freed of adhering fat 
and placed in liquid nitrogen for transport to our 
laboratory. Tissues were processed on the same day. All 
subsequent procedures were performed on ice. Pooled 
tissues (2.3 g total wet wt) were minced with razor 
blades and homogenized in ice-cold homogenization 
buffer with a 7-ml Dounce tissue grinder (Kontes Glass 
Co., Vineland, NJ) with a loose- and a tight-fitting pestle. 
The homogenate was filtered twice through nylon 
netting of 50 and 140 mesh, respectively, to remove 
cell debris. This full hom ogenate was diluted with 
homogenization buffer to a concentration of 21 mg 
protein/ml.
Preparation of subcellular fractions
Crude subcellular fractions were obtained by differential 
centrifugation at 4°C. After centrifugation at 1000#  for 
15 min in a Sorvall RC24 with a SM24 fixed-angle 
rotor, a crude nuclear pellet was obtained. The resulting 
supernatant was centrifuged at 10 0 0 0 #  for 2 0 m in  in 
the same rotor to obtain a mitochondrial pellet. The
10 0 0 0 #  supernatant was centrifuged subsequently at
108 000 g for 60 min in an MSE Prepspin 75 with a SP- 
2818 fixed-angle rotor, resulting in a microsomal pellet 
and a supernatant containing the cytosol. All pellets 
were resuspended in homogenization buffer with a 
glass-glass tissue grinder (Kontes) to 4 (mitochondrial 
fraction), 8 (microsoma] fraction) and 9 mg protein/ml 
(crude nuclear fraction). Aliquots of 1 ml were stored at 
-8 0 °C  and assayed within 4 weeks.
Protein levels were determined by a method modified 
from Lowry et al. (24) against a standard of bovine 
serum albumin (OHRD 20/21, Hoechst-Behring, 
Marburg, Germany). The assay was modified for 
microtitre plates and had a sensitivity of 2 5 fig per well.
5 a.~Reductase assay
The assay has been described and validated in detail 
in earlier papers (25, 26). In short, radiolabelled 
testosterone was diluted isotopically to a range of 
2 nm ol/1-3 /¿mol/1 (final concentration, 10 duplicate 
points), dissolved in incubation buffer (800 /¿l) in Pyrex 
culture tubes (borosilicate glass, 12 x 75 mm, Corning 
Inc., NY) and subsequently preheated at 37°C. For the 
inhibition experiments, the specific rat Sa-reductase 
type II inhibitor L-685,273 was added from stock 
solutions in ethanol (10pm ol/l-10 //m ol/l final concen­
tration) simultaneously with testosterone (30 nmol/1 
final concentration). This inhibitor is type II specific 
with inhibition constants of 0.04 nmol/1 for type II and 
2.8 nmol/1 for type 1 5a-reductase, respectively (16). 
Ten to 100 [A of the enzyme preparation (40 /¿g-2.1 mg 
protein) and the appropriate amount of co-factor 
(NADPH, 2 nmol/1 final concentration) was supple­
mented to 200 fA with incubation buffer and added to 
the tubes with substrate to start the incubation. After 
30 min the incubation was terminated by adding 
100 ^1 of 3 mol/1 NaOH, and metabolites were 
extracted with 4 ml of ice-cold diethyl ether. Percentile 
metabolism ranged from 1% to 16%. Extracted 
metabolites were reconstituted in 1 0 0 /¿I of hexane 
for HPLC.
High-performance liquid chromatography
Metabolized steroids were separated on a Hibar 
LiChrosorb Diol column (length 2 50 mm, 5 /xm, 
Merck) equipped with a guard column (Resolve Silica, 
Waters Corp., Milford, MA). The HPLC system included 
a Waters 610 fluid unit, a Waters 600E system 
controller and a Waters U6K injector. The isocratic 
flow of the mobile phase (hexane/propanol 9 6 :4 ,  v/v) 
was 1.5 ml/min at a pressure of 680 psi. Radioactivity 
was monitored with a FloOne Beta Radiomatic A500 
radio-chromatography detector (Packard-Canberra 
Benelux, Tilburg, The Netherlands) with a 500- ¡A cell 
and a liquid scintillation flow of 1.5 ml/min (Aqua- 
Luma, Lumac-LSC, Olen, Belgium). The counting 
efficiency for tritium was 47%. The percentage formation
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of DIIT a n d  5 a - a n d n ) S la n c - 3 a ( /3 ) I 7 / j - d io l  (Adiol) was 
used to estimate 5«-reductase activity.
Calculation oj enzyme characteristics
Velocities were plotted against testosterone concentra­
tions (over 30 duplicate points), and Km and Vmax 
values were calculated using a non-linear regression 
procedure to least-squares, based on a Michaelis- 
Menten equation for two independent isozyme activ­
ities. with the computer program Enzfitter. A double 
reciprocal plot (Lineweaver-Burk) of the estimated 
initial velocities obtained against substrate concentra­
tion was used. Furthermore, an Eadie-Scatchard plot of 
velocity over substrate concentration against velocity 
was also used, as this plot is reportedly best suited to 
detect isozyme activities (27). The IC50 values were 
determined from plots of enzyme velocity against 
inhibitor concentration.
Statistical analysis
Values were obtained in at least two duplicate assays 
carried out on different days. Statistical analysis was 
performed using a Pearson correlation test or analysis of 
variance and, when ANOVA revealed a statistically 
significant difference, a subsequent two-tailed Bonferroni 
(Dunn) ¿-testing with the SAS statistical software 
program.
Results
The validity of the 5a:-reductase assay was established 
and reported in earlier papers (25, 26). Initial velocity 
data were obtained at a substrate concentration range 
of 2 nmol/1-3 /¿mol/1 testosterone (Fig. 1A) and plotted 
according to Lineweaver-Burk (Fig. IB) and to Eadie- 
Scatchard (Fig. 1C). The best fits for isozyme activities 
are presented as solid lines in these figures. Line­
weaver-Burk plots deviated from linearity only at the 
higher substrate concentrations. Eadie-Scatchard plots, 
however, were clearly non-linear and could be 
described by two enzyme activities as shown by two 
additional lines in Fig. 1C. All subcellular fractions 
exhibited similar non-iinear plots (data not shown).
In Table 1 the data obtained in crude subcellular 
fractions from rat prostate are summarized. Approxi­
mately 70% of total protein was recovered in the 
subcellular fractions. The total recovery of enzymatic 
activity was 72.4% for type I and 73.7% for type II 
5a-reductase, respectively. For the type I isozyme, 
analysis of variance revealed differences in yield 
between fractions (p <  0.002). The yield of type I 
activity was highest in the nuclear fraction (Fig. 2A). 
The mitochondrial and microsomal fraction contained 
three-to fourfold less type I 5a-reductase activity as 
compared to the nuclear fraction (p < 0.005 by two- 
sided Bonferroni ¿-test). No significant differences in
yield were found for the type II isozyme between the 
subcellular fractions (p >  0.4 by ANOVA), approxi­
mately 25% of total activity being present in each of the 
three fractions. No 5a-reductase activity was found in 
the 108 0 0 0 #  supernatant (cytosol).
For both isozymes the specific activities in the 
subcellular fractions were all higher than  in the full 
homogenate (Table 1). The enrichment values for 
the isozymes, calculated as the ratio of specific activity 
in the subcellular fraction over that in the full
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Fig, 1, Detecting isozyme activities of rat prostatic 5a-reductase. Best lit 
for isozyme activity is presented by solid lines. (A) Initial velocities (V) 
were obtained at 2 nmol/1-3 testosterone and 2 mmol/1
NADPH at 3 7°C in a full homogenate of rat prostate. Values are 
means of at least two duplicate experiments carried out on two different 
days. (B) A double-reciprocal (Lineweaver-Burk) plot of these data 
deviates from linearity only at high testosterone concentrations. (C) An 
Eadie-Scatchard plot of V/substrate concentration (S) against V is
clearly non-linear. Activities of type I (--------) and type It (----- ) 5a-
reductase isozymes can be calculated from these data.
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Tabic 1. Protein and 5o-reductase isozyme data obtained in crude subcellular fractions of rat prostate.
Subtype
Protein 
(mg) (%)
Activity 
(pmol/min) (%)
Speciiic activity 
(pmol ■ m i n '1 ■ mg ’ protein)
Kra
(ninol/l)
1 II 1 II I II
Full homogenate 341.7 (100) 1010.7 (100) 48.2 (100) 2.96 0.141 528 7.2
Nuclei (1000 i/ pellet) 59.2 (16.5) 472.2 (46.7) 13.4 (27.8) 7.97 0.226 613 4.9
Mitochondria (10 000 0 pellet) 20.1 (5.8) 150.7 (14.9) 10.8 (22.4) 7.50 0.538 458 4.8
Microsomes (108 000# pellet) 15.7(4 .6) 109.4(10.8) 11.3 (23.5) 6.97 0.722 577 5.2
Cytosol (108 000 g supernatant) 149.7 (43.0) — —
homogenate, are shown in Fig* 2B. No significant 
differences between the values in nuclei, mitochondria 
and microsomes can be seen for the type I isozyme 
(p >  0.7 by ANOVA). The enrichment for this isozyme 
was approximately 2.5 in all three fractions. For the 
type II isozyme activity the enrichment differed between 
fractions (p <  0.02 by ANOVA). Highest purification 
was achieved in the microsomal fraction (five times 
higher specific activity), and lowest enrichment (1.6 
times) in the nuclear fraction. The values for the type II 
isozyme in the mitochondrial and microsomal fractions 
were significantly higher than  that in the nuclear 
fraction (p <  0.1 and p <  0.05, respectively, by the 
two-sided Bonferroni i-test).
The affinity constants for the type I isozyme were 
approximately 5 0 0 -6 0 0  nmol/1 in the full homogenate 
as well as in the subcellular fractions (Table 1). The type 
II isozyme activity had a Km of approximately 5 nmol/I. 
These affinity constants did not differ significantly 
between the subcellular fractions (p >  0.8 by ANOVA).
To corroborate the isozyme activity assay and to
substantiate further the subcellular distribution results, 
two other characteristics of Sa-reductase isozymes, i.e. 
pH dependency of velocities and inhibitor sensitivity, 
were investigated in the same subcellular fractions. The 
ratios of Vmax values of both isozyme activities obtained 
with Eadie-Scatchard plots (Vmax I/II) in the subcellular 
fractions were correlated with isozyme-specific pH- 
dependent velocity ratios (v pH 7.0/pH 5.0) (Fig. 3A). 
The activities at pH 7.0 and pH 5.0 are generally 
considered indicative of type I and type II isozyme 
activity, respectively (28). Initial velocities were 
estimated with 1 /¿mol/1 testosterone and 2 mmol/l 
NADPH at pH 7.0 and at pH 5.0. A high positive 
correlation of 0.942 (p < 0.025) between the ratios in 
the different subcellular fractions was found using the 
Pearson correlation test. The microsomal fraction 
exhibited the lowest isozyme type I over type II Vmax 
ratio and isozyme-specific pH-dependent velocity ratio 
(approximately 10 and 0,32, respectively); the crude 
nuclear fraction, on the other hand, exhibited the highest 
values (approximately 35 and 0.78, respectively). The
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Fig. 2. Sa-Reductase activities in crude subcellular fractions of rat prostate. Values are presented for the type I (solid bars) and type Ii (open bars) 
isozyme activities. (A) Percentile 5a~reductase isozyme activity (yield) in the different subcellular fractions. Values are means +  si> of at least two 
duplicate assays carried out on different days. The recoveries of type I activity in mitochondrial and microsomal fractions were significantly less 
as compared to the nuclear fraction. No significant differences between fractions were found for the type II isozyme activities. (B) Enrichment 
values (relative specific activities) were calculated as the ratio of speciiic activity in the subcellular fractions over that in the full homogenate. 
Values are means +  sd  of at least two duplicate assays carried out on different days. The type ii isozyme showed significantly higher purification 
in the mitochondrial and microsomal fractions as compared to the nuclear fraction. No significant differences between fractions were found for
the type I isozyme activities; *p <  0.1, **p <  0.05 and ***p < 0.005.
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Fig. S. Validation of isozyme activity measurements and their subcellular distribution. (A) Initial velocities were obtained with 1 /¿mol/1 
testosterone and 2 mmol/I NADPH at both pH 7.0 («type I) and pH 5.0 (»type II) in subcellular fractions of rat prostate. The ratio of velocities at 
pH 7.0 over pH 5.0 (v pH 7/pH 5.0) were correlated with isozyme Vmax ratio values calculated as described in Fig. 1 (Vmax I/II). A positive 
correlation of 0.942 (p < 0.025) was found using the Pearson correlation test. (B) Full homogenate, crude nuclear, mitochondrial and 
microsomal fractions were incubated as described in the Materials and Methods section with 30 nmol/l testosterone and 10 pm ol/I-10  \imol/1 of 
the specific rat 5a-reductase type II inhibitor b-685,273. The it1™ values were calculated and correlated with isozyme Vmax ratio values obtained 
as described in Fig. 1. A positive correlation of 0.856 (p <  0.05) was found using the Pearson correlation test.
1 0 0 0 0 #  pellet (mitochondria) and the full homogenate 
exhibited intermediate values.
Because of the differences in affinity constants for 
testosterone, the contribution to total 5a-reductase 
activity of each isozyme depends on the substrate 
concentration. The testerone concentration used for the 
inhibition experiments (30 nmol/l was chosen so that 
each isozyme would have an almost similar contribu­
tion to total 5a~reductase activity. This relative 
contribution will depend on the ratio of isozyme 
activities. Therefore, differences in rc50 values at a 
fixed substrate concentration can be attributed to 
differences in isozyme activity ratios in the subcellular 
fractions. Initial velocities were estimated at 10 pm ol/I- 
10/¿mmol/I of the specific rat 5a-reductase type II 
inhibitor L-685,273. The rc50 values were 5, 10 and
7 nmol/l for the full homogenate, mitochondrial and 
microsomal fractions, respectively, but 30 nmol/l for the 
crude nuclear fraction. As shown in Fig. 3B, the 
correlation between these ic50 values and the type I 
over type II Vmax ratios was statistically significant 
(0.856; p <  0.05, Pearson correlation test).
Discussion
To gain better insight into the differential roles of the 
two hitherto known 5a:-reductase isozymes expressed in 
the ra t prostate (16), the activities of both isozymes 
were evaluated in crude subcellular fractions. The rat 
prostate has been used as a model for the hum an 
prostate because growth and development of both 
tissues are androgen-dependent, both contain high 
5a-reductase activity and because of the notable
similarity between the hum an and rat 5a-reductase 
subtypes.
The ra t and hum an type I 5a~reductase isozymes 
have been reported to have a Km for testosterone of 
about 0 . 5 - 1 /xmol/1 (16, 25, 26), whereas the type II 
isozymes have a Km, at neutral pH, of 4 - 5 0  nm ol/l (25, 
26, 29, 30). As the substrate concentration should 
ideally be in the neighbourhood of the Km (27), 
subcellular fractions of the rat prostate were incubated 
with a wide range of testosterone concentrations of
2 nmol/1-3 /imol/1. A Lineweaver-Burk plot of these 
data only deviated from linearity at high substrate 
concentrations, whereas Eadie-Scatchard plots were 
clearly non-linear over essentially the whole substrate 
range tested.
The non-linearity of these plots might indicate 
negative cooperative binding of testosterone to 5a- 
reductase (27). We propose, however, tha t this non- 
linearity can be explained better by the presence of two 
5a-reductase isozyme activities. The affinity constants 
obtained (approximately 500 and 5 nmol/l for the 
alleged type I and type II activities, respectively) are 
similar to those reported in the literature for the rat 
and hum an  steroid 5a-reductase isozymes at neutral 
pH (16, 25, 26, 29, 30). In addition, data obtained 
with Eadie-Scatchard plots and isozyme-specific pH- 
dependent enzyme velocity ratios were closely related. 
Generally, the type II isozyme is considered to have an 
acidic pH optimum (16). Velocities at pH 5.0 do not 
properly reflect type II in vivo activity, as this isozyme is 
now considered to operate at neutral pH (30). The ratio 
between activity at pH 7.0 and pH 5.0, however, does 
represent differences in isozyme activity ratios (28). The
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correlation between data obtained by Eadie-Scatchard 
plots at pH 7.0 and the ratios of enzyme activity at 
pH 7.0 and pH 5.0 was indeed highly significant. 
Furthermore, the correlation between isozyme Vmax 
ratios and IC50 values of the type II-specific inhibitor 
L-685,273 in the subcellular fractions of the rat 
prostate was also significant. Altogether, these data 
strongly indicate the presence of two isozyme activities, 
resulting in the non-linear Eadie-Scatchard plots.
The sub-cellular localization of 5a-reductase in the 
rat prostate has been considered nuclear, both for 
enzymatic activity (6, 7, 17, 20, 22) and immuno- 
reactivity (23). In the ra t liver, type I 5a-reductase has 
been localized in the microsomal fraction (17), although 
this has been contended in a recent paper (31). To the 
best of our knowledge, the subcellular localization of the 
isozyme activities in the ra t prostate has not yet been 
elucidated. The results presented in this paper indicate a 
differential subcellular distribution of the two known 
subtypes of 5a-reductase in the ra t prostate. Highest 
purification was obtained for the type II isozyme in the 
microsomal fraction. Furthermore, almost half of the 
type I activity sedimented in the 1000 g pellet. However, 
the specific activity of the type I isozyme was similar in 
all three subtractions. This might be attributed to the 
difficulty in obtaining pure subcellular fractions due to 
the structural continuity between the outer nuclear 
membrane and the rough endoplasmatic reticulum, 
which has also led to controversy on the subcellular 
localization of the 5a-rcductase type I isozyme in rat 
liver (31). The Sa-reductase enzymatic activity found in 
the 10 000 ij pellet (crude mitochondrial fraction) can 
be attributed to contam ination with nuclear and 
microsomal m em brane particles. This 4‘mitochondrial'’ 
5a-reductase has also been found by other authors 
applying differential centrifugation to obtain subcellular 
fractions (6, 18, 20). A lthough the present study does 
not overcome the contam ination problems associated 
with differential centrifugation as reported for the 
hum an prostate (21), either isozyme activity can serve 
as a m arker for the other. If the isozyme activity ratio 
differs between subcellular fractions, as indeed is 
described here, a differential subcellular distribution 
can be surmised. This ratio of isozyme activity can only 
differ between fractions if the isozymes are differentially 
localized. Furthermore, the results on pH-dependent 
velocity ratios and inhibitor sensitivities in the crude 
subcellular fractions confirmed our conclusion on the 
subcellular distribution of isozyme activities. Surpris­
ingly, it was the type I isozyme that appeared 
predominantly— although not exclusively— nuclear- 
bound, whereas the type II isozyme had a more 
microsomal localization.
Dihydrotestosterone formed by the nuclear type I 
isozyme will more likely bind to the androgen receptor, 
also located in the nucleus (32, 33), than  that formed 
by the microsomal type II isozyme. This suggests an 
anabolic role for the 5a-reductase type I in this tissue.
Because in the rat prostate a high am ount of 3a//3- 
hydroxysteroid dehydrogenase (HSOR) activity is pres­
ent in the cytoplasm (34), any DHT formed by the type
II in the endoplasmatic reticulum would instantly be 
degraded to Adiol. Therefore, our results unexpectedly 
suggested a possibly catabolic role for the type II 
isozyme in the rat prostate.
However, in hypothesizing about the function of the 
5a~reductase isozymes, their cell-type specific localiza­
tion should also be considered. Type I 5a-reductase is 
expressed in the epithelial cells of the rat prostate (23,
3 5). In the DHT-dependent epithelium (36), nuclear- 
bound 5a~reductase type I (this study) would metabo­
lize testosterone to DHT to bind to the androgen 
receptor, suggesting a role of this subtype in the 
intracrinology of this tissue (42). On the other hand, 
DHT formed by the type II in the endoplasmatic 
reticulum (this study) of rat prostatic stromal cells 
(35) is metabolized extensively to Adiol (34), which has 
been shown to induce benign prostatic hyperplasia 
(BPH) in the dog (39). Stromal signals act on the 
epithelium in the development of certain glands (37, 38). 
Dihydrotestosterone and Adiol formed by the type II 
isozyme could therefore act as paracrine factors in 
this tissue, influencing epithelial cell fate.
Finally, another possible distinction in the roles of 5a- 
reductase might be considered. The high affinity of the 
type II 5a-reductase isozyme makes it well suited for 
metabolizing the low concentrations of testosterone in 
fetal life (30), leading to the hypothesis that it is the 
type II isozyme that is responsible for the development of 
the prostate. At the higher testosterone concentrations 
in adulthood, type I 5a-reductase might also contribute 
to DHT formation, and therefore be responsible for 
growth and maintenance of the prostate (35). Because 
of the poor development of prostates in patients with 
5a~reductase type II deficiency (pseudohermaphroditism) 
(40), a type II inhibitor (Finasteride, ProscarUl) has 
been developed for treatment of patients with BPH 
symptoms (41). Recently, in addition to type II, we 
reported type I Sa-reductase activity in human prostate 
with BPH (26), necessitating research into this subtype 
and into its possible involvement in the pathogenesis of
BPH.
In conclusion, Eadie-Scatchard plots of 5a-reductase 
activities, pH-dependent isozyme-specific velocity ratios 
and inhibitor sensitivities reported in this paper indicate a 
differential distribution of isozyme activities, i.e. a nuclear 
localization of the type I and a microsomal localization of 
the type II 5a-reductase isozyme in the rat prostate. To 
elucidate their roles, the cell-type specific localization of 
isozyme activities and the expression during ontogeny 
should also be taken into account.
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